Response to Helicobacter pylori Eradication Triple Therapy in Peptic Ulcer Disease Patients on Curcumin Supplement According to different ABO Phenotypes

Abstract

Background: Helicobacter pylori infection is one of the most predominant causes of pepticulcer disease. There was a correlation between H. pylori infection and ABO phenotypes in pepticulcer disease patients. Curcumin has anti- H. pylori effect due to its anti-oxidant, antiinflammatory,anti- microbial, and anti-carcinogenic effect.Patients and Methods: This study is a prospective randomized interventional open-label studywhich designed to show the potential benefit of adjuvant curcumin therapy in peptic ulcerdisease Iraqi patients with different ABO phenotypes. The patients were allocated into twogroups, group (1) treated with standard triple H. pylori eradication, and group (2) treated withcurcumin capsules as adjuvant with the standard triple therapy for two weeks. The ABOphenotypes detected by Anti ABO and Anti-D monoclonal kit and the H. pylori infection wasdetected at the baseline and after 6 weeks of completion treatment course.Results: highly significant improvement in H. pylori eradication after addition adjuvant curcuminto standard H. pylori eradication triple therapy compared to standard triple therapy alone(P<0.01)for patients holding blood group AB phenotypes ( P<0.01) and significant improvement forpatients holding blood group O phenotypes( P<0.05) reach up to (100 %) after 6 weeks from theintervention starting point. Besides, there was improvement in H. pylori eradication for patientsholding blood group A and B phenotypes with adjuvant curcumin therapy, though no significant(P>0.05). This study showed no significant difference in BMI among ABO phenotypes (A,B,AB, and O) for both groups 1 and 2 patients after 6 weeks from the intervention startingpoint(P>0.05).